Management of gastric mucosa-associated lymphoid tissue lymphoma

Digestive Diseases

Volumn 33, Issue 1, 2014, Pages 11-18

  Neumeister, Peter ^a   Troppan, Katharina ^a   Raderer, Markus ^b  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Eradication; Helicobacter pylori; Mucosa associated lymphoid tissue lymphoma; Therapy

Indexed keywords

AMOXICILLIN; ANTHRACYCLINE; ANTIBIOTIC AGENT; BENDAMUSTINE; BISMUTH; BORTEZOMIB; CHLORAMBUCIL; CLADRIBINE; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; ESOMEPRAZOLE; LENALIDOMIDE; LEVOFLOXACIN; METRONIDAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RITUXIMAB; TETRACYCLINE;

ANTIBIOTIC THERAPY; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; DISEASE ASSOCIATION; ERADICATION THERAPY; GASTRIC MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; LYMPHOID TISSUE; MARGINAL ZONE LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATHOGENESIS; REVIEW; STOMACH; STOMACH BIOPSY; STOMACH LYMPHOMA; STOMACH MUCOSA; LYMPHOMA, B-CELL, MARGINAL ZONE; MICROBIOLOGY; PATHOLOGY; PHYSIOLOGY;

HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; NEOPLASM STAGING;

EID: 84919782351     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000366030     Document Type: Review

References (54)

1. Isaacson PG, Chott A, Nakamura S, Müller- Hermelink HK, Harris NL, Swerdlow SH: Extranodal marginal zone lymphoma of mucosa- associated lymphoid tissue (MALT lymphoma); in Swerdlow SH, Campo E, Harris NL, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds): WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed 4. Lyon, IARC, 2008, pp 214-217.
2. Thieblemont C, Bastion Y, Berger F, Rieux C, Salles G, Dumontet C, Felman P, Coiffier B: Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients. J Clin Oncol 1997; 15: 1624-1630.
3. Isaacson PG, Du MQ: MALT lymphoma: from morphology to molecules. Nat Rev Cancer 2004; 4: 644-653.
4. Farinha P, Gascoyne RD: Molecular pathogenesis of mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 2005; 23: 6370-6378.
5. Farinha P, Gascoyne RD: Helicobacter pylori and MALT lymphoma. Gastroenterology 2005; 128: 1579-1605.
6. Parsonnet J, Isaacson PG: Bacterial infection and MALT lymphoma. N Engl J Med 2004; 350: 213-215.
7. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG: Helicobacter pylori -associated gastritis and primary B-cell gastric lymphoma. Lancet 1991; 338: 1175-1176.
8. Eck M, Schmausser W, Haas R, et al: MALTtype lymphoma of the stomach is associated with Helicobacter pylori strains expressing the CagA protein. Gastroenterology 1997; 112: 1482-1486.
9. Doglioni C, Wotherspoon AC, Moschini A, Deboni M, Isaacson PG: High incidence of primary gastric lymphoma in northeastern Italy. Lancet 1992; 339: 834-835.
10. Fischbach W, Goebeler-Kolve ME, Dragosics B, Greiner A, Stolte M: Long-term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series. Gut 2004; 53: 34-37.
11. Wündisch T, Thiede C, Morgner A, Dempfle A, Günther A, Liu H, Ye H, Du MQ, Kim TD, Bayerdörffer E, Stolte M, Neubauer A: Longterm follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol 2005; 23: 8018-8024.
12. Sagaert X, Van Cutsem E, De Hertogh G, Geboes K, Tousseyn T: Gastric MALT lymphoma: a model of chronic inflammation-induced tumor development. Nat Rev Gastroenterol Hepatol 2010; 7: 336-346.
13. Ruskoné-Fourmestraux A, Fischbach W, Aleman BM, Boot H, Du MQ, Megraud F, Montalban C, Raderer M, Savio A, Wotherspoon A; EGILS group: EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut 2011; 60: 747-758.
14. Liu H, Ye H, Ruskone-Fourmestraux A, De Jong D, Pileri S, Thiede C, Lavergne A, Boot H, Caletti G, Wündisch T, Molina T, Taal BG, Elena S, Thomas T, Zinzani PL, Neubauer A, Stolte M, Hamoudi RA, Dogan A, Isaacson PG, Du MQ: T(11; 18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology 2002; 122: 1286-1294.
15. Lévy M, Copie-Bergman C, Gameiro C, Chaumette MT, Delfau-Larue MH, Haioun C, Charachon A, Hemery F, Gaulard P, Leroy K, Delchier JC: Prognostic value of translocation t(11; 18) in tumoral response of lowgrade gastric lymphoma of mucosa-associated lymphoid tissue type to oral chemotherapy. J Clin Oncol 2005; 23: 5061-5066.
16. Streubel B, Ye H, Du MQ, Isaacson PG, Chott A, Raderer M: Translocation t(11; 18) (q21;q21) is not predictive of response to chemotherapy with 2CdA in patients with gastric MALT lymphoma. Oncology 2004; 66: 476-480.
17. Martinelli G, Laszlo D, Ferreri AJ, Pruneri G, Ponzoni M, Conconi A, Crosta C, Pedrinis E, Bertoni F, Calabrese L, Zucca E: Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti- Helicobacter pylori therapy. J Clin Oncol 2005; 23: 1979-1983.
18. Zucca E, Copie-Bergman C, Ricardi U, Thieblemont C, Raderer M, Ladetto M; ESMO Guidelines Working Group: Gastric marginal zone lymphoma of MALT type: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 (suppl 6):vi144-148.
19. Raderer M, Wöhrer S, Streubel B, Troch M, Turetschek K, Jäger U, Skrabs C, Gaiger A, Drach J, Puespoek A, Formanek M, Hoffmann M, Hauff W, Chott A: Assessment of disease dissemination in gastric compared with extragastric mucosa-associated lymphoid tissue lymphoma using extensive staging: a single-center experience. J Clin Oncol 2006; 24: 3136-3141.
20. Ruskoné-Fourmestraux A, Lavergne A, Aegerter PH, Megraud F, Palazzo L, de Mascarel A, Molina T, Rambaud JL: Predictive factors for regression of gastric MALT lymphoma after anti- Helicobacter pylori treatment. Gut 2001; 48: 297-303.
21. Musshoff K: Clinical staging classification of non-Hodgkin's lymphomas (in German). Strahlentherapie 1977; 153: 218-221.
22. Radaskiewicz T, Dragosics B, Bauer P: Gastrointestinal malignant lymphomas of the mucosa-associated lymphoid tissue: factors relevant to prognosis. Gastroenterology 1992; 102: 1628-1638.
23. Ruskoné-Fourmestraux A, Dragosics B, Morgner A, Wotherspoon A, De Jong D: Paris staging system for primary gastrointestinal lymphomas. Gut 2003; 52: 912-913.
24. Zullo A, Hassan C, Cristofari F, Andriani A, De Francesco V, Ierardi E, Tomao S, Stolte M, Morini S, Vaira D: Effects of Helicobacter pylori eradication on early stage gastric mucosaassociated lymphoid tissue lymphoma: a review. Clin Gastroenterol Hepatol 2010; 8: 105-110.
25. Morgner A, Lehn N, Andersen LP, Thiede C, Bennedsen M, Trebesius K, Neubauer B, Neubauer A, Stolte M, Bayerdörffer E: Helicobacter heilmannii -associated primary gastric low-grade MALT lymphoma: complete remission after curing the infection. Gastroenterology 2000; 118: 821-828.
26. Bayerdörffer E, Oertel H, Lehn N, Kasper G, Mannes GA, Sauerbruch T, Stolte M: Topographic association between active gastritis and Campylobacter pylori colonisation. J Clin Pathol 1989; 42: 834-839.
27. Lehous P: Ruskone-Fourmestraux A, Lavergne A, Cantet F, Mégraud F; Groupe d'Etude des Lymphomes Digestifs (GELD) for the Fédération Française de Cancérologie Digestive (FFCD): Which test to use to detect Helicobacter pylori infection in patients with low-grade gastric mucosa-associated lymphoid tissue lymphoma ? Am J Gastroenterol 2003; 98: 291-295.
28. Gisbert JP, Calvet X: Review article: common misconceptions in the management of Helicobacter pylori -associated gastric MALT lymphoma. Aliment Pharmacol Ther 2011; 34: 1047-1062.
29. Gatta L, Vakil N, Ricci C, Osborn JF, Tampieri A, Perna F, Miglioli M, Vaira D: Effect of proton pump inhibitors and antacid therapy on 13C urea breath tests and stool test for Helicobacter pylori infection. Am J Gastroenterol 2004; 99: 823-829.
30. Graham DY, Opekun AR, Hammoud F, Yamaoka Y, Reddy R, Osato MS, El-Zimaity HM: Studies regarding the mechanism of false negative urea breath tests with proton pump inhibitors. Am J Gastroenterol 2003; 98: 1005-1009.
31. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ; European Helicobacter Study Group: Management of Helicobacter pylori infection - the Maastricht IV/Florence Consensus Report. Gut 2012; 61: 646-664.
32. Gisbert JP, Calvet X, O'Connor A, Mégraud F, O'Morain CA: Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol 2010; 44: 313-325.
33. Villoria A, Garcia P, Calvet X, Gisbert JP, Vergara M: Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2008; 28: 868-877.
34. Zullo A, Hassan C, Andriani A, Cristofari F, De Francesco V, Ierardi E, Tomao S, Morini S, Vaira D: Eradication therapy for Helicobacter pylori in patients with gastric MALT lymphoma: a pooled data analysis. Am J Gastroenterol 2009; 104: 1932-1937.
35. Fischbach LA, van Zanten S, Dickason J: Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti- Helicobacter pylori quadruple therapies. Aliment Pharmacol Ther 2004; 20: 1071-1082.
36. Zullo A, Haasan C, Ridola L, De Francesco V, Rossi L, Tomao S, Vaira D, Genta RM: Eradication therapy in Helicobacter pylori -negative, gastric low-grade mucosa-associated lymphoid tissue lymphoma patients: a systematic review. J Clin Gastroenterol 2013; 47: 824-827.
37. Fischbach W, Goebeler ME, Ruskone-Fourmestraux A, Wündisch T, Neubauer A, Raderer M, Savio A; EGILS (European Gastro-Intestinal Lymphoma Study) Group: Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be managed safely by a watch and wait strategy: experience from a large international series. Gut 2007; 56: 1685-1687.
38. Nakamura S, Sugiyama T, Matsumoto T, Iijima K, Ono S, Tajika M, Tari A, Kitadai Y, Matsumoto H, Nagaya T, Kamoshida T, Watanabe N, Chiba T, Origasa H, Asaka M; Japan GAST Study Group: Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori : a multicentre cohort follow-up study of 420 patients in Japan. Gut 2012; 61: 507-513.
39. Troch M, Woehrer S, Streubel B, Weissel M, Hoffmann M, Müllauer L, Chott A, Raderer M: Chronic autoimmune thyroiditis (Hashimoto's thyroiditis) in patients with MALT lymphoma. Ann Oncol 2008; 19: 1336-1339.
40. Wöhrer S, Troch M, Streubel B, Zwerina J, Skrabs C, Formanek M, Hauff W, Hoffmann M, Müllauer L, Chott A, Raderer M: MALT lymphoma in patients with autoimmune diseases: a comparative analysis of characteristics and clinical course. Leukemia 2007; 21: 1812-1818.
41. Copie-Bergman C, Wotherspoon AC, Capella C, Motta T, Pedrinis E, Pileri SA, Bertoni F, Conconi A, Zucca E, Ponzoni M, Ferreri AJ: GELA histological scoring system for posttreatment biopsies of patients with gastric MALT lymphoma is feasible and reliable in routine practice. Br J Haematol 2013; 160: 47-52.
42. Koch P, Berdel WE, Willich NA, Reinartz G, Brockmann J, Liersch R, del Valle F, Clasen H, Hirt C, Breitsprecher R, Schmits R, Freund M, Fietkau R, Ketterer P, Freitag EM, Hinkelbein M, Heinecke A, Parwaresch R, Tiemann M: Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96). J Clin Oncol 2005; 23: 7050-7059.
43. Zullo A, Hassan C, Andriani A, Cristofari F, Bassanelli C, Spinelli GP, Tomao S, Morini S: Treatment of low-grade gastric MALT lymphoma unresponsive to Helicobacter pylori therapy: a pooled-data analysis. Med Oncol 2010; 27: 291-295.
44. Avilés A, Nambo MJ, Neri N, Talavera A, Cleto S: Mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach: results of a controlled clinical trial. Med Oncol 2005; 22: 57-62.
45. Wirth A, Gospodarowicz M, Aleman BM, Bressel M, Ng A, Chao M, Hoppe RT, Thieblemont C, Tsang R, Moser L, Specht L, Szpytma T, Lennard A, Seymour JF, Zucca E: Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study. Ann Oncol 2013; 24: 1344-1351.
46. Tsang RW, Gospodarowicz MK, Pintilie M, Wells W, Hodgson DC, Sun A, Crump M, Patterson BJ: Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. Clin Oncol 2003; 21: 4157-4164.
47. Hammel P, Haioun C, Chaumette MT, Gaulard P, Divine M, Reyes F, Delchier JC: Efficacy of single-agent chemotherapy in lowgrade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression. J Clin Oncol 1995; 13: 2524-2529.
48. Jäger G, Neumeister P, Quehenberger F, Wöhrer S, Linkesch W, Raderer M: Prolonged clinical remission in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type treated with cladribine: 6-year follow-up of a phase II trial. Ann Oncol 2006; 17: 1722-1723.
49. Jäger G, Höfler G, Linkesch W, Neumeister P: Occurrence of a myelodysplastic syndrome (MDS) during first-line 2-chloro-deoxyadenosine (2-CDA) treatment of a low-grade gastrointestinal MALT lymphoma. Case report and review of the literature. Haematologica 2004; 89:ECR01.
50. Martinelli G, Laszlo D, Ferreri AJ, Pruneri G, Ponzoni M, Conconi A, Crosta C, Pedrinis E, Bertoni F, Calabrese L, Zucca E: Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti- Helicobacter pylori therapy. J Clin Oncol 2005; 23: 1979-1983.
51. Zucca E, Conconi A, Laszlo D, López-Guillermo A, Bouabdallah R, Coiffier B, Sebban C, Jardin F, Vitolo U, Morschhauser F, Pileri SA, Copie-Bergman C, Campo E, Jack A, Floriani I, Johnson P, Martelli M, Cavalli F, Martinelli G, Thieblemont C: Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 randomized study. J Clin Oncol 2013; 31: 565-572.
52. Salar A, Domingo-Domenech E, Panizo C, Nicolás C, Bargay J, Muntanola A, Canales M, Bello JL, Sancho JM, Tomas JF, Rodriguez MJ, Penalver FJ, Palomera L, Grande C, Sánchez- Blanco JJ, Arranz R, Conde E, Caballero D, Montalban C: Final results of a multicenter phase ii trial with bendamustine and rituximab as first line treatment for patients with MALT lymphoma (MALT-2008-01). ASH Ann Meet Abstracts. Blood 2012; 120: 3691.
53. Kiesewetter B, Troch M, Dolak W, Müllauer L, Lukas J, Zielinski CC, Raderer M: A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma). Haematologica 2013; 98: 353-356.
54. Kiesewetter B, Fridrik M, Willenbacher W, Willenbacher E, Greil R, Marku Raderer M: Rituximab plus lenalidomide in patients with MALT-lymphoma: AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie) MALT 2 Study. ICML, Lugano, 2013.